Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?   

The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study met its endpoint of overall survival. Does this change your practice at all? 

Answer from: Medical Oncologist at Community Practice
Medical Oncologist at Virginia Cancer Specialists
With even lower numbers of patients with ALK gene ...
Sign in or Register to read more